Preparation for the prevention and/or treatment of vascular disorders

• US 8,865,687 B2
• Filed: 02/14/2013
• Issued: 10/21/2014
• Est. Priority Date: 05/08/2000
• Status: Expired due to Fees

• Current Assignee: nv nutricia
• Original Assignee: nv nutricia
• Inventors: Kiliaan, Amanda Johanne, Hageman, Robert Johan Joseph
• Primary Examiner(s): DAVIS, RUTH A
• Application Number:
  US13/767,730
• Publication Number:
  US 20130157978A1
• Time in Patent Office: 614 Days
• Field of Search: 514/165, 514/494, 514/560, 514/551, 514/882, 424/725, 424/752, 530/350
• US Class Current: 514/165
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A23L 33/115 Fatty acids or derivatives thereof; Fats or oils
• CPC Class Codes: A23L 33/15 Vitamins
• CPC Class Codes: A23L 33/16 Inorganic salts, minerals or trace elements
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2250/032 Citric acid
• CPC Class Codes: A23V 2250/156 Mineral combination undefined extract A23V2250/1638
• CPC Class Codes: A23V 2250/161 Magnesium
• CPC Class Codes: A23V 2250/1642 Zinc
• CPC Class Codes: A23V 2250/1842 Lecithin
• CPC Class Codes: A23V 2250/1846 Phosphatidyl Choline
• CPC Class Codes: A23V 2250/1848 Phosphatidyl Ethanolamine
• CPC Class Codes: A23V 2250/1852 Phosphatidyl Serine
• CPC Class Codes: A23V 2250/5114 Dextrins, maltodextrins
• CPC Class Codes: A23V 2250/704 Vitamin B
• CPC Class Codes: A23V 2250/7052 Vitamin B6
• CPC Class Codes: A23V 2250/706 Vitamin B12
• CPC Class Codes: A23V 2250/716 Vitamin M
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/14 Quaternary ammonium compounds, e.g. edrophonium, choline betaines A61K31/205
• CPC Class Codes: A61K 31/194 : having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• CPC Class Codes: A61K 31/20 : having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
• CPC Class Codes: A61K 31/202 : having three or more double bonds, e.g. linolenic eicosanoids, e.g. leukotrienes A61K31/557
• CPC Class Codes: A61K 31/205 : Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• CPC Class Codes: A61K 31/355 : Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/4415 : Pyridoxine, i.e. Vitamin B6 pyridoxal phosphate A61K31/675
• CPC Class Codes: A61K 31/519 : ortho- or peri-condensed with heterocyclic rings
• CPC Class Codes: A61K 31/683 : Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
• CPC Class Codes: A61K 31/685 : one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• CPC Class Codes: A61K 33/30 : Zinc; Compounds thereof
• CPC Class Codes: A61K 33/34 : Copper; Compounds thereof
• CPC Class Codes: A61K 36/16 : Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
• CPC Class Codes: A61K 45/06 : Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 25/16 : Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/06 : Antihyperlipidemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 : Antihypertensives

Abstract

The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions:

• • fraction a) consisting of long chain polyunsaturated fatty acids;
  • fraction b) consisting of phospholipids, which fraction contains at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine.
  • fraction c) consisting of compounds which are a factor in methionine metabolism, which fraction contains at least one member selected from the group consisting of folic acid, vitamin B12, vitamin B6, magnesium and zinc.

Claims

1. A method for treating a person suffering from or being at risk of degeneration of cerebral function, cognitive degeneration and/or dementia syndromes associated with vascular disorders;

vascular degeneration of cerebral function, vascular cognitive degeneration, vascular dementia and/or Alzheimer'"'"'s disease, the method comprising administering to a person in need thereof a preparation, comprising;

a) at least 120 mg per daily dosage of a long chain polyunsaturated fatty acid (LCPUFA) fraction comprising docosahexaenoic acid (DHA);

b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and

c) folic acid and vitamin B6, wherein the amount of folic acid is at least 200 μ

g per daily dosage.

2. The method according to claim 1, wherein said person suffering from or being at risk of degeneration of cerebral function, cognitive degeneration and/or dementia syndromes associated with vascular disorders is a person suffering from or being at risk of Alzheimer'"'"'s disease, vascular dementia, presenile dementia, senile dementia, atherosclerotic dementia, Parkinson'"'"'s and Huntington'"'"'s disease.

3. The method according to claim 1, wherein the preparation further comprises choline and/or carnitine.

4. The method according to claim 1, wherein the preparation further comprises 1.5-30 g citrate and/or citric acid per daily dose.

5. The method according to claim 4, wherein the preparation further comprises more than 2.4 g citrate and/or citric acid per daily dose.

6. The method according to claim 1, wherein the LCPUFA fraction comprises omega-3 and omega-6 LCPUFAs in a ratio of omega-3:

omega-6 LCPUFAs of 2.5 to 5.5 wt/wt.

7. The method according to claim 1, wherein the preparation further comprises eicosapentaenoic acid (EPA).

8. The method according to claim 1, wherein the LCPUFA fraction further comprises linoleic acid (LA) and/or alpha-linolenic acid (ALA) and one omega-6 fatty acid selected from dihomogammlinolenic acid (DHGLA) and arachidonic acid (AA), and the ratio of the total amount of EPA+DHA+DHGLA+AA to the total amount of LA and ALA is larger than 0.4:

1.

9. The method according to claim 1, further comprising vitamin C and/or vitamin E.

10. The method according to claim 1, wherein the amount of folic acid is at least 400 μ

g per daily dosage.

11. The method according to claim 1, wherein the amount of vitamin B6 is more than 2 mg vitamin B6 per daily dose.

12. The method according to claim 1, wherein the preparation is a liquid, concentrate or powder.

13. The method according to claim 1, wherein the person is suffering from or being at risk of degeneration of vascular degeneration of cerebral function, vascular cognitive degeneration, vascular dementia and/or Alzheimer'"'"'s disease.

14. A method for treating a person suffering from or being at risk of vascular disorders or secondary disorders associated therewith, the method comprising administering to a person in need thereof a preparation, comprising:

a) at least 120 mg of a long chain polyunsaturated fatty acid fraction comprising docosahexaenoic acid (DHA) and optionally eicosapentaeonic acid (EPA);

b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and

c) folic acid and vitamin B6, wherein the amount of folic acid is at least 200 μ

g per daily dosage.

15. A method for treating a person suffering from or being at risk of degeneration of cerebral function, cognitive degeneration and/or dementia syndromes associated with vascular disorders;

vascular degeneration of cerebral function, vascular cognitive degeneration, vascular dementia and/or Alzheimer'"'"'s disease, the method comprising administering to a person in need thereof a preparation, comprising;

a) 120-2000 mg per daily dosage of EPA and DHA collectively, of which at least 50 mg of the daily dosage is DHA;

b) at least two different phospholipids selected from the group consisting of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine; and

c) folic acid and vitamin B6, wherein the amount of folic acid is at least 200 ng per daily dosage.

16. The method according to claim 15, wherein said person suffering from or being at risk of degeneration of cerebral function, cognitive degeneration and/or dementia syndromes associated with vascular disorders is a person suffering from or being at risk of Alzheimer'"'"'s disease, vascular dementia, presenile dementia, senile dementia, atherosclerotic dementia, Parkinson'"'"'s and Huntington'"'"'s disease.

17. The method according to claim 15, wherein the preparation further comprises choline and/or carnitine.

18. The method according to claim 15, comprising omega-3 and omega-6 long chain polyunsaturated fatty acids (LCPUFAs) in a ratio of omega-3:

omega-6 LCPUFAs of 2.5 to 5.5 wt/wt.

19. The method according to claim 15, wherein the preparation further comprises linoleic acid (LA) and/or alpha-linolenic acid (ALA) and one omega-6 fatty acid selected from dihomogammlinolenic acid (DHGLA) and arachidonic acid (AA), and the ratio of the total amount of EPA+DHA+DHGLA+AA to the total amount of LA and ALA is larger than 0.4:

1.

20. The method according to claim 15, wherein the preparation further comprises vitamin C and/or vitamin E.

21. The method according to claim 15, wherein the amount of folic acid is at least 400 ng per daily dosage.

22. The method according to claim 15, wherein the amount of vitamin B6 is more than 2 mg vitamin B6 per daily dose.

23. The method according to claim 15, wherein the preparation is a liquid, concentrate or powder.

24. The method according to claim 15, wherein the person is suffering from or being at risk of vascular degeneration of cerebral function, vascular cognitive degeneration, vascular dementia and/or Alzheimer'"'"'s disease.